Table 6.
Clinical data of patients in the validation set.
| Characteristics | Patients, n (%) 1 |
|---|---|
| Age at diagnosis, mean ± S.D. 2 (years) | 58.9 ± 12.5 |
| Menopausal status | |
| Premenopausal | 197 (25) |
| Postmenopausal | 590 (75) |
| Missing data | 18 |
| Tumor size (pT) | |
| pTis | 65 (8) |
| pT1 | 489 (62) |
| pT2 | 208 (27) |
| pT3 | 18 (2) |
| pT4 | 10 (1) |
| pTX | 15 |
| Lymph node metastasis (pN) | |
| Absent (pN0) | 509 (67) |
| Present (pN1-3) | 253 (33) |
| pNX | 43 |
| Pathological stage | |
| S0 | 61 (8) |
| SI | 358 (47) |
| SII | 282 (37) |
| SIII | 67 (9) |
| Not determined | 37 |
| Histological type | |
| Invasive ductal carcinoma | 598 (25) |
| Other type | 197 (75) |
| Missing data | 10 |
| Pathological grade (G) | |
| G1 | 177 (23) |
| G2 | 385 (50) |
| G3 | 209 (27) |
| GX | 34 |
| Estrogen receptor status | |
| Positive | 618 (77) |
| Negative | 181 (23) |
| Missing data | 6 |
| Progesterone receptor status | |
| Positive | 579 (73) |
| Negative | 220 (27) |
| Missing data | 6 |
| Expression of HER2 | |
| Positive | 194 (24) |
| Negative | 602 (76) |
| Missing data | 9 |
| Expression of Ki-67, mean ± S.D. 2 (%) | 23.3 ± 22.6 |
| Molecular subtype | |
| Luminal A | 330 (41) |
| Luminal B | 313 (39) |
| Triple negative | 93 (12) |
| HER2 | 63 (8) |
| Missing data | 6 |
| Response to neoadjuvant cytotoxic therapy | |
| Complete or partial response | 127 (75) |
| Stable disease or progression | 43 (25) |
| Not applicable 3 | 635 |
Footnotes. 1 Number of patients with % in parentheses; 2 S.D. = standard deviation; 3 patients treated with adjuvant therapy without neoadjuvant cytotoxic therapy.